U.S. FDA authorizes marketing of PMI’s nicotine pouches
Following an extensive scientific review, the FDA determined that the nicotine pouches receiving marketing authorization met the public health standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act. This standard considers the risks and benefits of products to the population as a whole.
The FDA’s evaluation showed that, because they contained substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products, the authorized products pose lower risk of cancer and other serious health conditions.
In the announcement, the FDA noted that the agency had reviewed “evidence from a study showing that a substantial proportion of adults who use cigarette and/or smokeless tobacco products completely switched to the newly authorized nicotine pouch products.” The FDA also reviewed “data regarding youth risk and found that youth use of nicotine pouches remains low despite growing sales in recent years.”
Read more about PMI’s nicotine pouches, including the science behind them, here.
